Patients who received augmentation in anterior cruciate ligament (ACL) reconstruction with bone marrow aspirate concentrate (BMAC) containing concentrated stem cells showed accelerated healing and better range of motion at 9 months, according to a study presented at the Radiological Society of North America 106th Scientific Assembly and Annual Meeting (RSNA 2020). The study was titled A Prospective Randomized Trial of Biologic Augmentation with Mesenchymal Stem Cells in Patients Undergoing Anterior Cruciate Ligament Reconstruction.
ACL tears are common and devastating injuries among young athletes, and re-injury poses a significant threat to both successful return to play and long-term outcomes. Graft healing during ACL reconstruction is a slow process.
This is the first study to examine BMAC augmentation in ACL reconstruction.
“Given the high incidence of ACL tears, management of this condition has significant consequences for athletes’ return to play,” says study co-author Ophelie Lavoie-Gagné.
This was a randomized controlled trial examining injection of BMAC into an ACL allograft versus a sham incision with ACL reconstruction. A total of 43 patients were enrolled with .no significant differences in gender, age, or time to injury. Bone marrow aspirate was harvested from the anterior-superior iliac crest, concentrated via centrifuge, and injected into the allograft. MRI was performed at 3 and 9 months post-operatively.
MRI findings at 3 months in the BMAC group showed significantly higher signal intensity in the inferior third of the allograft and the BMAC group demonstrated significantly higher patient-reported outcome measures and knee range of motion on physical exam.Back To Top
RSNA 2020: Stem Cell Treatment Speeds Healing, Range of Motion After ACL Tear. Appl Radiol.